Vizgen raises $85.2M for Series C Financing


Vizgen, a Cambridge, MA-based life science company, closed an $85.2 million Series C financing.

Blue Water Life Science Advisors led the round with participation from Sofina Venture Partners, Northpond Ventures and Tao Capital Partners. Novalis LifeSciences was also involved.

The company plans to use the funds for growth and expansion of operations.

Vizgen’s CEO Terry Lo is committed to providing tools that allow researchers to gain new insights into biological systems that regulate human health and disease. The company’s MERSCOPE Platform – based on the MERFISH technology developed in the laboratory of Dr. Xiaowei Zhuang, a Howard Hughes Medical Institute Investigator, and the David B. Arnold, Jr. Professor of Science at Harvard University – enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE is a vital tool to accelerate drug discovery and development. It provides insights into a broad range of tissue-scale basic and translational research in oncology and immunology as well as cell and gene therapy.

Vizgen announced broad U.S. availability of its platform in January 2022.

Get latest news from African Startup ecosystem

Latest stories

You might also like...